ATE340560T1 - Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten - Google Patents

Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten

Info

Publication number
ATE340560T1
ATE340560T1 AT00936279T AT00936279T ATE340560T1 AT E340560 T1 ATE340560 T1 AT E340560T1 AT 00936279 T AT00936279 T AT 00936279T AT 00936279 T AT00936279 T AT 00936279T AT E340560 T1 ATE340560 T1 AT E340560T1
Authority
AT
Austria
Prior art keywords
compositions
methods
treatment
transfer
gene therapy
Prior art date
Application number
AT00936279T
Other languages
English (en)
Inventor
Rajagopal Ramesh
Jack A Roth
Tomoyuki Saeki
Deborah Wilson
Original Assignee
Introgen Therapeutics Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Introgen Therapeutics Inc, Univ Texas filed Critical Introgen Therapeutics Inc
Application granted granted Critical
Publication of ATE340560T1 publication Critical patent/ATE340560T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
AT00936279T 1999-05-24 2000-05-24 Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten ATE340560T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13581899P 1999-05-24 1999-05-24

Publications (1)

Publication Number Publication Date
ATE340560T1 true ATE340560T1 (de) 2006-10-15

Family

ID=22469835

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00936279T ATE340560T1 (de) 1999-05-24 2000-05-24 Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten

Country Status (7)

Country Link
EP (1) EP1180016B1 (de)
AT (1) ATE340560T1 (de)
AU (1) AU5161800A (de)
CA (1) CA2371922C (de)
DE (1) DE60030970T2 (de)
ES (1) ES2273699T3 (de)
WO (1) WO2000071096A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1854488A1 (de) * 1999-07-15 2007-11-14 Introgen Therapeutics, Inc. Methoden zur Behandlung von hyperproliferativen Krankheiten mit menschlichem MDA-7
US20080038274A1 (en) * 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
EP1404359A2 (de) * 2000-12-07 2004-04-07 Board Of Regents, The University Of Texas System Behandlungsverfahren mit menschlichem mda-7
US6656732B1 (en) 2001-05-18 2003-12-02 Isis Pharmaceuticals, Inc. Antisense inhibition of src-c expression
EP3100719A3 (de) 2002-05-15 2017-02-22 California Pacific Medical Center Zuführung von nukleinsäureähnlichen verbindungen
WO2005082396A2 (en) 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
CN1318591C (zh) * 2004-07-08 2007-05-30 杨安钢 免疫tbid基因及其编码的蛋白和应用
DK2302055T3 (da) 2004-11-12 2014-10-13 Asuragen Inc Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
PT2056882E (pt) 2006-08-01 2012-11-19 Univ Texas Identificação de um micro-rna que ativa a expressão da cadeia pesada de beta-miosina
AU2008210434C8 (en) 2007-01-31 2014-03-27 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
BRPI0809366B8 (pt) 2007-03-28 2021-05-25 Harvard College polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
AU2007356036A1 (en) * 2007-06-29 2009-01-08 Newsouth Innovations Pty Limited Treatment of rheumatoid arthritis
EP2419529B1 (de) 2009-04-14 2015-05-20 Nestec S.A. Prognostik entzündlicher darmerkrankung
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
ES2631458T3 (es) 2010-03-04 2017-08-31 Interna Technologies B.V. Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
CA2804599C (en) 2010-07-06 2023-01-31 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
US8859723B2 (en) 2010-08-13 2014-10-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2474617A1 (de) 2011-01-11 2012-07-11 InteRNA Technologies BV MIR zur Behandlung von Neoangiogenese
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
EP2769321B1 (de) 2011-10-21 2016-06-01 Nestec S.A. Verfahren zur verbesserung der diagnose einer entzündlichen darmerkrankung
US10174314B2 (en) 2011-12-22 2019-01-08 Interna Technologies B.V. MiRNA for treating head and neck cancer
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
EP2917348A1 (de) 2012-11-06 2015-09-16 InteRNA Technologies B.V. Kombination zur behandlung von erkrankungen oder zuständen im zusammenhang mit melanom oder behandlung von erkrankungen und zuständen im zusammenhang mit aktivierten b-raf-signalweg
US20150337375A1 (en) 2012-12-21 2015-11-26 The Trustees Of Columbia University In The City Of New York Biomarkers for chronic traumatic encephalopathy
CA2905949A1 (en) 2013-03-15 2014-09-25 Baylor Research Institute Ulcerative colitis (uc)-associated colorectal neoplasia markers
EP3068783B1 (de) 2013-11-15 2020-09-23 The Board of Trustees of the Leland Stanford Junior University Agonisten des hypokretin-rezeptors 2 zur verwendung zur behandlung von herzversagen
WO2015074010A2 (en) 2013-11-18 2015-05-21 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration
CN105316380B (zh) * 2014-06-20 2021-03-09 浙江海洋学院 泥螺多肽在抗肺癌中的应用
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
GB201503967D0 (en) 2015-03-09 2015-04-22 Univ Glasgow Biocompatible implants for use in tendon therapy
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
EP3347372A4 (de) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Peptidomimetische makrocyclen als modulatoren von mcl-1
US20200123499A1 (en) 2015-12-02 2020-04-23 Massachusetts Institute Of Technology Method for efficient generation of neurons from non-neuronal cells
PL3691655T3 (pl) 2017-10-03 2022-01-24 Aptahem Ab Cząsteczka kwasu nukleinowego o właściwościach przeciwzapalnych, przeciwkrzepliwych i chroniących narządy
US11497762B2 (en) 2017-11-03 2022-11-15 Interna Technologies B.V. MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
AU2019352354A1 (en) * 2018-10-05 2021-05-13 International Institute Of Cancer Immunology, Inc. Prophylactic or therapeutic drug for benign tumor
WO2023070072A1 (en) 2021-10-21 2023-04-27 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Retroelement-generated transcription factor decoys
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023183589A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Rt-dna fidelity and retron genome editing
WO2023183627A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
WO2023183588A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of assessing engineered retron activity, and uses thereof
WO2023196725A1 (en) 2022-04-07 2023-10-12 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Continuous multiplexed phage genome engineering using a retron editing template
WO2024044673A1 (en) 2022-08-24 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Dual cut retron editors for genomic insertions and deletions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105914A0 (en) * 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
CA2263705C (en) * 1996-08-19 2007-12-04 Nancy Smyth-Templeton Novel sandwich liposome complexes comprising a biologically active agent
JP2001510457A (ja) * 1996-11-12 2001-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ送達に有効な、脂質―核酸複合体の安定な製剤の調製

Also Published As

Publication number Publication date
CA2371922C (en) 2012-03-27
DE60030970D1 (de) 2006-11-09
WO2000071096A2 (en) 2000-11-30
DE60030970T2 (de) 2007-09-06
WO2000071096A3 (en) 2001-05-03
EP1180016B1 (de) 2006-09-27
CA2371922A1 (en) 2000-11-30
AU5161800A (en) 2000-12-12
ES2273699T3 (es) 2007-05-16
EP1180016A2 (de) 2002-02-20

Similar Documents

Publication Publication Date Title
ATE340560T1 (de) Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
DE69534669D1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
EP1140971A4 (de) Antisens-modulierung von neuartigen anti-apoptotischen bcl-2-artigen proteinen
EP1325019A4 (de) Antisense-modulation der clusterinexpression
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
EP1414842A4 (de) Antisense-modulation der expression von acyl-coa-cholesterin-acyltransferase-2
ATE290403T1 (de) Verbesserung der verabreichung der nukleinsäure in zellen der plurizellulären eukaryotischen organismen und kombination zur durchführung des verfahrens
ATE445417T1 (de) Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
DE69837274D1 (de) Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten
WO2003008543A3 (en) Antisense modulation of bcl2-associated x protein expression
WO2003014306A3 (en) Antisense modulation of cholesteryl ester transfer protein expression
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
WO2003018600A3 (en) Antisense modulation of microsomal triglyceride transfer protein expression
WO1998032846A3 (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos
WO2002064737A3 (en) Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
EP1185696A4 (de) Modifikation der expression der menschlichen proteinkinase c-delta mit hilfe von antisense-oligonukleotiden
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
BR9810452A (pt) Nova combinação de medicamentos contra asma
FR2801592B1 (fr) Dendrimeres phosphores et leurs applications comme agents de transfection
HUP0402327A2 (hu) Inzulinszerű növekedési faktort kötő 5-ös fehérje expressziójának antiszensz módosítása
EP1277843A3 (de) Neue humane Gene und Genexpressionsprodukte die in Zusammenhang mit Darmkrebs stehen
ATE247978T1 (de) Verwendung von ompa enterobakterproteinen um zielgerichtet antigen-präsentierende zellen anzusteuern
WO2003044167A3 (en) Antisense modulation of human fxr expression
ATE278011T1 (de) Human dnase ii
DE60115622D1 (de) Methoden und zusammensetzungen zur aufklärung von proteinexpressionsprofilen in zellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties